Amgen is an international biotechnology company that makes an active contribution to better care. Amgen scientists have been developing innovative therapies for patients with serious illnesses since 1980. Our product portfolio encompasses the following therapeutic areas: oncology, kidney diseases, hematology, bone diseases and cardiovascular diseases.
Amgen is active in around 100 countries worldwide. Amgen Europe B.V. has been located in Breda since 1997. At this site, Amgen medicines are labeled, provided with patient information leaflets, packaged and distributed throughout Europe and to a growing number of countries in other parts of the world. The Dutch sales organization Amgen B.V. is also located in Breda. It is responsible for the availability of our medicines and clinical trials in the Netherlands.
Amgen has built up an excellent, worldwide reputation in the area of biologics - medicines made using biotechnological techniques. Amgen supplies high-quality medicines and focuses primarily on patients with conditions for which few or no treatment options exist. It takes expertise, experience, vigilance and dedication to ensure that every new batch of biologic medicines is of the same high quality. At Amgen, strict quality control and a reliable supply of medicines are just as important as scientific innovation.